Table 1.

Baseline characteristics

CharacteristicCKD, n=25Dialysis, n=9Transplant, n=23
Mean age (range), yr15.2 (11–21)15.3 (12–18)16.8 (11–21)
Race
 White12 (48%)2 (22%)14 (61%)
 Black10 (40%)4 (44%)6 (26%)
 Other3 (12%)3 (33%)3 (13%)
CKD stagea
 18 (32%)N/A5 (22%)
 25 (20%N/A9 (39%)
 310 (40%)N/A7 (30%)
 42 (8%)N/A1 (4%)
 509 (100%)1 (4%)
Dialysis
 HemodialysisN/A4 (44%)N/A
 Peritoneal dialysisN/A5 (56%)N/A
Baseline immunosuppressionb6 (24%)4 (44%)22 (96%)
Average no. of medications0.240.92.5
 Prednisone1 (4%)4 (44%)19 (83%)
 Tacrolimus1 (4%)2 (22%)17 (74%)
 Rapamycin01 (11%)3 (13%)
 Cyclosporin2 (8%)01 (4%)
 Mycophenolate mofetil2 (8%)1 (11%)15 (65%)
 Abatacept001 (4%)
 Leflunomide001 (4%)
Diagnosis
 Glomerular15 (60%)3 (33%)8 (35%)
 Nonglomerular10 (40%)3 (33%)13 (56%)
 Unknown03 (33%)2 (9%)
Time from transplant/dialysis, mo
 MedianN/A829
 Range0–600–163
 ≤125 (56%)6 (26%)
  • Data shown as n (%), unless otherwise indicated. N/A, not applicable.

  • a CKD stage by the National Kidney Foundation definition of eGFR: stage 1, ≥90 ml/min per 1.73 m2; stage 2, 60–89 ml/min per 1.73 m2; stage 3, 30–59 ml/min per 1.73 m2; stage 4, 15–29 ml/min per 1.73 m2; and stage 5, <15 ml/min per 1.73 m2.

  • b Immunosuppression is defined by the immunosuppressant medication at vaccine 1: prednisone, tacrolimus, cyclosporin, mycophenolate mofetil, or rapamycin.